The growth of the EPS is critical in understanding the current valuation of Blueprint Medicines Corporation. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 28.50 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Blueprint Medicines Corporation is making for it’s investors or shareholders.
Blueprint Medicines Corporation is part of the biotechnology industry and is part of the healthcare sector. The company CEO is Jeffrey W. Albers. Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
Previous Intraday Performance:
The BPMC shares had a previous change of 1.15% which opened at 56.89 and closed at 57.37. It moved to an intraday high of 58.40 and a low of 55.90.
Historical Performance:
Over the last five trading days, BPMC shares returned -0.83% and in the past 30 trading days it returned -15.53%. Over three months, it changed -21.31%. In one year it has changed -18.58% and within that year its 52-week high was 109.00 and its 52-week low was 50.51. BPMC stock is 13.58% above its 52 Week Low.
Our calculations result in a 200 day moving average of 75.20 and a 50 day moving average of 65.25. Right now, BPMC stock is trading -23.71% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
Liquidity:
The company has a market cap of $2.5b with 44.0m shares outstanding and a float of 43.3m shares. Trading volume was 253,504 shares and has experienced an average volume of 456,569 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
Earnings:
The last annual reported EPS for Blueprint Medicines Corporation was -3.91 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -1.57.
Below was the last reported quarterly earnings per share:
09-30-2018: -1.66
06-30-2018: -0.62
03-31-2018: -1.29
12-31-2017: -1.23
Indicators Also to Watch:
Based on the latest filings, there is 1.40% of insider ownership and 113.20% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.39
SeekingAlpha: Tracking Wallace Weitz’s Weitz Investment Management Portfolio – Q3 2018 Update
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -49.45%, return on assets is -40.02%, price-to-sales is 55.25 and price-to-book is 5.15.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Biotechnology, Blueprint Medicines Corporation, BPMC, Healthcare
